Literature DB >> 24136197

Understanding the role of argininosuccinate lyase transcript variants in the clinical and biochemical variability of the urea cycle disorder argininosuccinic aciduria.

Liyan Hu1, Amit V Pandey, Sandra Eggimann, Véronique Rüfenacht, Dorothea Möslinger, Jean-Marc Nuoffer, Johannes Häberle.   

Abstract

Argininosuccinic aciduria (ASA) is an autosomal recessive urea cycle disorder caused by deficiency of argininosuccinate lyase (ASL) with a wide clinical spectrum from asymptomatic to severe hyperammonemic neonatal onset life-threatening courses. We investigated the role of ASL transcript variants in the clinical and biochemical variability of ASA. Recombinant proteins for ASL wild type, mutant p.E189G, and the frequently occurring transcript variants with exon 2 or 7 deletions were (co-)expressed in human embryonic kidney 293T cells. We found that exon 2-deleted ASL forms a stable truncated protein with no relevant activity but a dose-dependent dominant negative effect on enzymatic activity after co-expression with wild type or mutant ASL, whereas exon 7-deleted ASL is unstable but seems to have, nevertheless, a dominant negative effect on mutant ASL. These findings were supported by structural modeling predictions for ASL heterotetramer/homotetramer formation. Illustrating the physiological relevance, the predominant occurrence of exon 7-deleted ASL was found in two patients who were both heterozygous for the ASL mutant p.E189G. Our results suggest that ASL transcripts can contribute to the highly variable phenotype in ASA patients if expressed at high levels. Especially, the exon 2-deleted ASL variant may form a heterotetramer with wild type or mutant ASL, causing markedly reduced ASL activity.

Entities:  

Keywords:  Argininosuccinate Lyase (ASL); Argininosuccinic Aciduria (ASA); Computer Modeling; Homomeric/Heterotetrameric Protein; Metabolic Diseases; Recombinant Protein Expression; Transcript Variants; Transfection; Urea Cycle

Mesh:

Substances:

Year:  2013        PMID: 24136197      PMCID: PMC3843073          DOI: 10.1074/jbc.M113.503128

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Assessment of protein models with three-dimensional profiles.

Authors:  R Lüthy; J U Bowie; D Eisenberg
Journal:  Nature       Date:  1992-03-05       Impact factor: 49.962

2.  WHAT IF: a molecular modeling and drug design program.

Authors:  G Vriend
Journal:  J Mol Graph       Date:  1990-03

3.  Characterization and enzyme activity of argininosuccinate lyase/delta-crystallin of the embryonic duck lens.

Authors:  J Piatigorsky; J Horwitz
Journal:  Biochim Biophys Acta       Date:  1996-07-18

4.  Molecular analysis of human argininosuccinate lyase: mutant characterization and alternative splicing of the coding region.

Authors:  D C Walker; D A McCloskey; L R Simard; R R McInnes
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

5.  A method to identify protein sequences that fold into a known three-dimensional structure.

Authors:  J U Bowie; R Lüthy; D Eisenberg
Journal:  Science       Date:  1991-07-12       Impact factor: 47.728

6.  Intragenic complementation at the human argininosuccinate lyase locus. Identification of the major complementing alleles.

Authors:  D C Walker; J Christodoulou; H J Craig; L R Simard; L Ploder; P L Howell; R R McInnes
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

Review 7.  Urea cycle disorders: diagnosis, pathophysiology, and therapy.

Authors:  S W Brusilow; N E Maestri
Journal:  Adv Pediatr       Date:  1996

8.  Errors in protein structures.

Authors:  R W Hooft; G Vriend; C Sander; E E Abola
Journal:  Nature       Date:  1996-05-23       Impact factor: 49.962

9.  Characterization of the human argininosuccinate lyase gene and analysis of exon skipping.

Authors:  R D Abramson; P Barbosa; K Kalumuck; W E O'Brien
Journal:  Genomics       Date:  1991-05       Impact factor: 5.736

10.  Analysis of naturally occurring and site-directed mutations in the argininosuccinate lyase gene.

Authors:  P Barbosa; M Cialkowski; W E O'Brien
Journal:  J Biol Chem       Date:  1991-03-15       Impact factor: 5.157

View more
  5 in total

1.  Identification of compound-protein interactions through the analysis of gene ontology, KEGG enrichment for proteins and molecular fragments of compounds.

Authors:  Lei Chen; Yu-Hang Zhang; Mingyue Zheng; Tao Huang; Yu-Dong Cai
Journal:  Mol Genet Genomics       Date:  2016-08-16       Impact factor: 3.291

2.  Unstable argininosuccinate lyase in variant forms of the urea cycle disorder argininosuccinic aciduria.

Authors:  Liyan Hu; Amit V Pandey; Cécile Balmer; Sandra Eggimann; Véronique Rüfenacht; Jean-Marc Nuoffer; Johannes Häberle
Journal:  J Inherit Metab Dis       Date:  2015-03-17       Impact factor: 4.982

3.  Effect of Cysteamine on Mutant ASL Proteins with Cysteine for Arginine Substitutions.

Authors:  Corinne Inauen; Véronique Rüfenacht; Amit V Pandey; Liyan Hu; Henk Blom; Jean-Marc Nuoffer; Johannes Häberle
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

4.  Whole-Exome Sequencing Identified a Novel Compound Heterozygous Genotype in ASL in a Chinese Han Patient with Argininosuccinate Lyase Deficiency.

Authors:  Mei Zhao; Lingling Hou; Huajing Teng; Jinchen Li; Jiesi Wang; Kunlin Zhang; Lin Yang
Journal:  Biomed Res Int       Date:  2019-04-30       Impact factor: 3.411

5.  Down-regulation of argininosuccinate lyase induces hepatoma cell apoptosis through activating Bax signaling pathway.

Authors:  Rui Gong; Lin He; HongZhong Zhou; ShengTao Cheng; Fang Ren; Juan Chen; JiHua Ren
Journal:  Genes Dis       Date:  2018-11-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.